Supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant 10892.
Disclosure: A. Miki, Sensimed (F), Santen Pharmaceuticals (R), R-Tech Ueno (R), Pfizer Japan (R), Otsuka Pharmaceuticals (R), Novartis Pharma (R), Topcon (R), Kowa Pharmaceuticals (R); N. Maeda, Alcon Laboratories, Inc. (C, R), JSPS Kakenhi (F), Santen Pharmaceuticals (R), Otsuka Pharmaceuticals (R), Topcon (R), Abbott Medical Optics (R), Johnson & Johnson (R), Tomey Corp. (R); Y. Ikuno, Bayer Yakuhin (C), Norvartis Phama (C), Tomey (F), Topcon (F); T. Asai, None; C. Hara, None; K. Nishida, Topcon (F), Menicon (F), Wakamoto (F), Rohto Pharmaceutical (F), MSD Japan (F), Senju Pharmaceutical (F, R), Pfizer Japan (F, R), Santen Pharmaceuticals (F, R), Otsuka Pharmaceutical (F, R), Novartis Pharma (F, R), Alcon Japan (F, R), HOYA (F, R), Kowa Pharmaceuticals (F, R), AMO Japan (F), Boehringer Ingelheim Japan (R), Bayer Yakuhin (R), SEED (R), Chuo Sangio (R), Johnson & Johnson Japan (R)